Comparative analysis of CDR3 length-dependent patterns in VHHs.

Front Immunol

Drug Discovery and Development, Chantibody Therapeutics, Menlo Park, CA, United States.

Published: September 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: VHHs, or nanobodies, are distinguished by their compact size, high stability, and unique ability to selectively target specific epitopes. The CDR3 region in VHHs, which plays a crucial role in antigen binding, exhibits significant diversity and varies among species.

Method: This study systematically examined CDR3 length dependent patterns by analyzing NGS sequences from the PBMCs of Alpacas, Llamas and Bactrians, in conjunction with VHH structure data from the public database.

Results: VHHs from Alpacas and Llamas exhibited similar CDR3 length distributions, while Bactrian VHHs displayed significantly longer but narrower length distribution. Key sequence, structural, and VHH/antigen interaction characteristics correlated with CDR3 length were identified. Specifically, longer CDR3s were associated with a lower net charge, reduced surface hydrophobicity, and enhanced interactions with other VHH regions. Structural analyses revealed that longer CDR3s tended to adopt bent conformations with increased helical and coil structures, whereas shorter CDR3s favored extended conformations and β-sheets. Associations between CDR3 length and amino acid usage patterns within VHH sequences were also observed, including preferences at various sites and in antigen interactions. Notably, species-specific differences were apparent, with Alpaca and Llama VHHs showing more pronounced CDR3 length-dependent patterns than those from Bactrians.

Discussion: These findings highlight the significant impact of CDR3 length on VHH sequence, structure, and antigen interaction characteristics, providing valuable insights for VHH engineering, synthetic library design, and the development of therapeutic nanobodies optimized for targeting diverse epitopes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394203PMC
http://dx.doi.org/10.3389/fimmu.2025.1647230DOI Listing

Publication Analysis

Top Keywords

cdr3 length
20
cdr3
8
cdr3 length-dependent
8
length-dependent patterns
8
alpacas llamas
8
interaction characteristics
8
longer cdr3s
8
vhhs
6
length
6
vhh
5

Similar Publications

Objective: To examine whether features of the B cell receptor (BCR) IgG repertoire correlate with disease activity and clinical phenotypes in systemic autoimmune diseases (SAIDs).

Methods: High-throughput sequencing was performed on IgG heavy chain repertoires from 138 patients with SAIDs, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma (SSc), and idiopathic inflammatory myopathy (IIM), as well as 36 healthy controls (HC). We analyzed V/D/J gene usage, clonal distribution and diversity, CDR3 length distribution and amino acid usage, and the correlation between specific BCR features and clinical features.

View Article and Find Full Text PDF

Comparative analysis of CDR3 length-dependent patterns in VHHs.

Front Immunol

September 2025

Drug Discovery and Development, Chantibody Therapeutics, Menlo Park, CA, United States.

Introduction: VHHs, or nanobodies, are distinguished by their compact size, high stability, and unique ability to selectively target specific epitopes. The CDR3 region in VHHs, which plays a crucial role in antigen binding, exhibits significant diversity and varies among species.

Method: This study systematically examined CDR3 length dependent patterns by analyzing NGS sequences from the PBMCs of Alpacas, Llamas and Bactrians, in conjunction with VHH structure data from the public database.

View Article and Find Full Text PDF

The Coronavirus disease 2019 (COVID-19) has rapidly become the worst pandemic since the 1918 influenza pandemic. Studies have shown that severe COVID-19 patients have immune dysfunction. To characterize the dysregulated immune response to SARS-CoV-2 infection, we performed a comprehensive analysis of scRNA-seq and scV(D)J-seq in peripheral blood mononuclear cells from mild, moderate, and severe patients.

View Article and Find Full Text PDF

Pre-treatment peripheral blood TCR repertoire as a predictor of response in patients with NSCLC treated with immunochemotherapy.

BMC Cancer

July 2025

Department of Pulmonary and Critical Care Medicine, The First Hospital, NHC Key Laboratory of Pneumoconiosis, Shanxi Province Key Laboratory of Respiratory Disease, Shanxi Medical University, Taiyuan, 030001, China.

Background: Although there has been progress in developing T-cell receptor (TCR)-based biomarkers to predict clinical benefit (CB) in patients treated with immune checkpoint blockade (ICB) therapy, studies on the circulating TCR repertoire in non-small cell lung cancer (NSCLC) remain limited. Therefore, further investigation and validation of the TCR repertoire as a potential biomarker for predicting the benefit of immune checkpoint inhibitor therapy are needed.

Methods: Blood samples were collected from patients with advanced NSCLC before initiating anti-programmed cell death 1 (anti-PD-1) antibody treatment in combination with chemotherapy.

View Article and Find Full Text PDF

Introduction: Pure red cell aplasia (PRCA), autoimmune hemolytic anemia (AIHA), and aplastic anemia (AA) are immune-mediated diseases that affect mainly erythrocytes or erythroid progenitor cells. This study aimed to investigate changes related to autoimmunity in B-cell receptor (BCR) and T-cell receptor (TCR) repertoires in patients with these diseases.

Methods: Patients with primary PRCA, AIHA, and AA and normal controls (NCs) were recruited.

View Article and Find Full Text PDF